Equitable Trust Co. Has $6.50 Million Holdings in Elanco Animal Health Incorporated $ELAN

Equitable Trust Co. raised its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 11.7% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 271,473 shares of the company’s stock after buying an additional 28,520 shares during the period. Equitable Trust Co.’s holdings in Elanco Animal Health were worth $6,496,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in ELAN. Hsbc Holdings PLC boosted its stake in shares of Elanco Animal Health by 92.3% during the 1st quarter. Hsbc Holdings PLC now owns 40,631 shares of the company’s stock worth $972,000 after acquiring an additional 19,502 shares during the period. Graetz Wealth LLC bought a new stake in Elanco Animal Health in the 1st quarter valued at $227,000. Kestra Advisory Services LLC raised its stake in Elanco Animal Health by 62.2% in the 1st quarter. Kestra Advisory Services LLC now owns 12,022 shares of the company’s stock valued at $288,000 after acquiring an additional 4,608 shares during the period. Oregon Public Employees Retirement Fund raised its stake in Elanco Animal Health by 3.1% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 101,892 shares of the company’s stock valued at $2,438,000 after acquiring an additional 3,092 shares during the period. Finally, Axxcess Wealth Management LLC acquired a new stake in Elanco Animal Health during the 1st quarter valued at $376,000. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Stock Down 0.2%

ELAN stock opened at $24.63 on Friday. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12. The stock has a market capitalization of $12.30 billion, a price-to-earnings ratio of -49.27, a PEG ratio of 1.61 and a beta of 1.68. The business’s fifty day moving average price is $23.39 and its two-hundred day moving average price is $23.77. Elanco Animal Health Incorporated has a fifty-two week low of $13.39 and a fifty-two week high of $27.72.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company’s revenue was up 14.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities analysts anticipate that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on ELAN shares. JPMorgan Chase & Co. lifted their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. TD Cowen increased their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Weiss Ratings downgraded shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. Finally, Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $28.55.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, CEO Jeffrey N. Simmons acquired 4,971 shares of the company’s stock in a transaction on Friday, May 15th. The stock was acquired at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the purchase, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Rajeev A. Modi acquired 4,911 shares of the business’s stock in a transaction on Friday, May 15th. The stock was acquired at an average cost of $20.35 per share, with a total value of $99,938.85. Following the acquisition, the insider directly owned 160,812 shares in the company, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 1.14% of the stock is currently owned by company insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.